BiondVax to start pivotal universal flu vaccine trial next year

BiondVax to start pivotal universal flu vaccine trial next year

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) expects to be Phase 3 ready in 2018 to begin pivotal testing in Europe of a universal flu vaccine with the potential to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.

Read More

Profound makes leap to platform company from prostate product

Profound makes leap to platform company from prostate product

With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on prostate cancer ablation to a platform company, offering real-time magnetic resonance (MR)-guidance as the imaging platform and ultrasound as the energy source for the delivery of non-invasive ablative technology to clinicians.

Read More

In conversation with Lloyd Segal of Repare

In conversation with Lloyd Segal of Repare

As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a leading healthcare investment firm with a hands-on approach to company building. Repare is developing precision oncology drugs that target specific vulnerabilities of tumor cells...

Read More

CKD patients opt to stay on Dimerix drug after trial

CKD patients opt to stay on Dimerix drug after trial

Forty-five per cent of patients in Dimerix’s (ASX:DXB) successful Phase 2a trial in chronic kidney disease (CKD), on advice from their physician, applied for and were granted access to remain on DMX-200 under Australia’s Special Access Scheme, which allows participants continued access to a therapy after they complete a clinical study.

Read More

Scientus enters commercialization stage of growth, readies launch of lead product

Scientus enters commercialization stage of growth, readies launch of lead product

Closely-held Scientus Pharma expects to launch its first cannabis soft gel capsules for the treatment of neuropathic pain at the end of the year, to be followed in early 2018 with a soft gel for epilepsy and post-traumatic stress disorder, and plans for a delayed-release capsule for pain later in 2018.

Read More

Appili readies antibiotic bridging study

Appili readies antibiotic bridging study

Closely-held Appili Therapeutics plans to begin late in the current quarter a Phase 1 bridging, or bioequivalence, study of its lead anti-infective, ATI-1501, a reformulated, taste-masked liquid suspension of metronidazole, targeting anaerobic bacterial infections, including Clostridium difficile.

Read More

PureTech targeting dysfunctions in brain, gut, immune system

PureTech targeting dysfunctions in brain, gut, immune system

With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious diseases caused by dysfunctions in the brain, gut and immune system.

Read More

In conversation with John Gannon of TempTraq

In conversation with John Gannon of TempTraq

As president and CEO of closely-held Blue Spark Technologies and co-inventor of its newest product, TempTraq, John Gannon’s career has stretched from the aerospace industry to Wall Street, culminating in 2011 with this developer of thin, flexible printed batteries built on IP from Eveready Battery, now Energizer. He has worked as an engineer in GE’s Astro-Space division and in currency derivatives with Merrill Lynch in New York and Barclays Capital in London...

Read More

Tetra Bio-Pharma sets active cannabis clinical programs

Tetra Bio-Pharma sets active cannabis clinical programs

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has an aggressive clinical trial program set to begin in the final quarter this year and first quarter of 2018 to prove the efficacy and safety of at least three therapeutic cannabis products.

Read More

Klox focused on oral care launch, partner for wound care

Klox focused on oral care launch, partner for wound care

With franchises in dermatology, wound care and oral health, closely-held Klox Technologies has three near-term milestones this year: launching its oral care business with Colgate Palmolive; expanding the Dermatology franchise; and seeking a marketing partner for its wound business care.

Read More

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He was a co-founder of Bedrocan Canada, one of Canada’s first licensed producers of medical cannabis, and founding chairman of the Cannabis Canada Association, a trade group with 17 licensed producers...

Read More

Medicenna targeting brain cancer with molecular Trojan horse

Medicenna targeting brain cancer with molecular Trojan horse

Medicenna Therapeutics (TSXV:MDNA) is advancing a targeted dual-action immunotherapeutic, MDNA55, that consists of an engineered version of interleukin-4 (IL-4) plus a tumor-killing cytotoxin for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.

Read More

In conversation with Thomas Ronk of Buyins.net

In conversation with Thomas Ronk of Buyins.net

As the founder and CEO of Buyins.net, Thomas Ronk has created a proprietary database and trading strategy based on short sale timing and sales data that was not accessible to anyone prior to January 2005. As a registered representative of Transamerica Financial Resources, a division of Transamerica, Mr. Ronk managed more than $150-million in equity accounts from 1993 until 1998. He has 27 years of trading experience...

Read More

IntelGenx has multi-faceted BD approach for its oral films

IntelGenx has multi-faceted BD approach for its oral films

With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing opportunities, and continuing to build its product pipeline jointly with R&D.

Read More

​​​​​​​In conversation with Yijun Huang

​​​​​​​In conversation with Yijun Huang

As a co-founder and chief technical officer of closely held EyeKor, which helps clients navigate the ever-changing landscape of ophthalmic clinical trials, Dr. Yijun Huang, a bioengineering executive, cut his teeth developing software and hardware solutions for ophthalmic imaging applications, both in academic and industrial situations. They include VP of engineering at Topcon Medical Systems, a major Japanese manufacturer of ophthalmic devices...

Read More